AstraZeneca digs into precision medicine with lung, heart deals
By Ben Hirschler LONDON (Reuters) – AstraZeneca is diving deeper into personalized healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease. Personalized or precision medicine, which tailors treatment to a patient's genetic profile, is an increasing focus for drug companies, especially after an initiative from U.S. President Barack Obama in January. “Up to now the science of personalized healthcare has been slower to reach those common disease areas such as cardiovascular and respiratory disease.” To redress the balance, AstraZeneca said on Wednesday it had signed two deals, one with Abbott Laboratories for a diagnostic test to accompany an experimental asthma drug and another with Canadian scientists on genes associated with heart disease.